Papillomavirus E6 proteins

Virology

Volumn 384, Issue 2, 2009, Pages 324-334

  Howie, Heather L ^a   Katzenellenbogen, Rachel A ^a,b   Galloway, Denise A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; E6 oncogene; HPV; hTERT; p53

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN E6; PROTEIN P53; TELOMERASE;

ANTIGEN RECOGNITION; APOPTOSIS; CANCER RISK; CELL ADHESION; CELL CYCLE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL POLARITY; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; DNA REPLICATION; DNA SYNTHESIS; ENZYME ACTIVITY; EPITHELIUM CELL; HOST CELL; HUMAN; NONHUMAN; ONCOGENE; PAPILLOMA VIRUS; PRIORITY JOURNAL; SHORT SURVEY; UTERINE CERVIX CANCER; VIRUS REPLICATION;

APOPTOSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL POLARITY; CELL TRANSFORMATION, VIRAL; CHROMOSOMAL INSTABILITY; GTP-BINDING PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

DNA VIRUSES; HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 59349104441     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.11.017     Document Type: Short Survey

References (156)

1. Allsopp R.C., Vaziri H., Patterson C., Goldstein S., Younglai E.V., Futcher A.B., Greider C.W., and Harley C.B. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 89 21 (1992) 10114-10118
2. Anderson C.J., Hoare S.F., Ashcroft M., Bilsland A.E., and Keith W.N. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 25 1 (2006) 61-69
3. Ashcroft M., and Vousden K.H. Regulation of p53 stability. Oncogene 18 53 (1999) 7637-7643
4. Barbosa M.S., Lowy D.R., and Schiller J.T. Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J. Virol. 63 (1989) 1404-1407
5. Barlev N.A., Liu L., Chehab N.H., Mansfield K., Harris K.G., Halazonetis T.D., and Berger S.L. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8 6 (2001) 1243-1254
6. Be X., Hong Y., Wei J., Androphy E.J., Chen J.J., and Baleja J.D. Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. Biochemistry. 40 5 (2001) 1293-1299
7. Bedard K.M., Underbrink M.P., Howie H.L., and Galloway D.A. The E6 oncoproteins from human betapapillomaviruses differentially activate telomerase through an E6AP-dependent mechanism and prolong the lifespan of primary keratinocytes. J. Virol. 82 8 (2008) 3894-3902
8. Bilder D. Epithelial polarity and proliferation control: links from the Drosophila neoplastic tumor suppressors. Genes Dev. 18 16 (2004) 1909-1925
9. Borbely A.A., Murvai M., Konya J., Beck Z., Gergely L., Li F., and Veress G. Effects of human papillomavirus type 16 oncoproteins on survivin gene expression. J. Gen. Virol. 87 Pt 2 (2006) 287-294
10. Breiding D.E., Sverdrup F., Grossel M.J., Moscufo N., Boonchai W., and Androphy E.J. Functional interaction of a novel cellular protein with the papillomavirus E2 transactivation domain. Mol. Cell. Biol. 17 12 (1997) 7208-7219
11. Bryan T.M., and Cech T.R. Telomerase and the maintenance of chromosome ends. Curr. Opin. Cell. Biol. 11 3 (1999) 318-324
12. Bryan T.M., Englezou A., Gupta J., Bacchetti S., and Reddel R.R. Telomere elongation in immortal human cells without detectable telomerase activity. Embo J. 14 17 (1995) 4240-4248
13. Cerezo A., Kalthoff H., Schuermann M., Schafer B., and Boukamp P. Dual regulation of telomerase activity through c-Myc-dependent inhibition and alternative splicing of hTERT. J. Cell. Sci. 115 Pt 6 (2002) 1305-1312
14. Chen J.J., Hong Y., Rustamzadeh E., Baleja J.D., and Androphy E.J. Identification of an alpha helical motif sufficient for association with papillomavirus E6. J. Biol. Chem. 273 22 (1998) 13537-13544
15. Cohen S.B., Graham M.E., Lovrecz G.O., Bache N., Robinson P.J., and Reddel R.R. Protein composition of catalytically active human telomerase from immortal cells. Science 315 5820 (2007) 1850-1853
16. Cole S.T., and Danos O. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J. Mol. Biol. 193 4 (1987) 599-608
17. Cong Y.S., Wen J., and Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum. Mol. Genet. 8 1 (1999) 137-142
18. Cooper K., Herrington C.S., Evans M.F., Gatter K.C., and McGee J.O. p53 antigen in cervical condylomata, intraepithelial neoplasia, and carcinoma: relationship to HPV infection and integration. J. Pathol. 171 1 (1993) 27-34
19. Crook T., Fisher C., Masterson P.J., and Vousden K.H. Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 9 4 (1994) 1225-1230
20. Crook T., Tidy J.A., and Vousden K.H. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67 (1991) 547-556
21. Crook T., Wrede D., and Vousden K.H. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6 5 (1991) 873-875
22. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19 18 (2005) 2100-2110
23. Degenhardt Y.Y., and Silverstein S. Interaction of zyxin, a focal adhesion protein, with the e6 protein from human papillomavirus type 6 results in its nuclear translocation. J. Virol. 75 23 (2001) 11791-11802
24. Degenhardt Y.Y., and Silverstein S.J. Gps2, a protein partner for human papillomavirus E6 proteins. J. Virol. 75 1 (2001) 151-160
25. Doorbar J., Foo C., Coleman N., Medcalf L., Hartley O., Prospero T., Napthine S., Sterling J., Winter G., and Griffin H. Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. Virology 238 1 (1997) 40-52
26. Du J., Chen G.G., Vlantis A.C., Chan P.K., Tsang R.K., and van Hasselt C.A. Resistance to apoptosis of HPV 16-infected laryngeal cancer cells is associated with decreased Bak and increased Bcl-2 expression. Cancer Lett. 205 1 (2004) 81-88
27. Duerksen-Hughes P.J., Yang J., and Schwartz S.B. HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells. Virology 264 1 (1999) 55-65
28. Elston R.C., Napthine S., and Doorbar J. The identification of a conserved binding motif within human papillomavirus type 16 E6 binding peptides, E6AP and E6BP. J. Gen. Virol. 79 Pt. 2 (1998) 371-374
29. Emerald B.S., Chen Y., Zhu T., Zhu Z., Lee K.O., Gluckman P.D., and Lobie P.E. AlphaCP1 mediates stabilization of hTERT mRNA by autocrine human growth hormone. J. Biol. Chem. 282 1 (2007) 680-690
30. Filippova M., Song H., Connolly J.L., Dermody T.S., and Duerksen-Hughes P.J. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 277 24 (2002) 21730-21739
31. Filippova M., Parkhurst L., and Duerksen-Hughes P.J. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 279 24 (2004) 25729-25744
32. Filippova M., Johnson M.M., Bautista M., Filippov V., Fodor N., Tungteakkhun S.S., Williams K., and Duerksen-Hughes P.J. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J. Virol. 81 8 (2007) 4116-4129
33. Fujiwara M., Kamma H., Wu W., Hamasaki M., Kaneko S., Horiguchi H., Matsui-Horiguchi M., and Satoh H. Expression and alternative splicing pattern of human telomerase reverse transcriptase in human lung cancer cells. Int. J. Oncol. 24 4 (2004) 925-930
34. Gao Q., Srinivasan S., Boyer S.N., Wazer D.E., and Band V. The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation. Mol. Cell. Biol. 19 1 (1999) 733-744
35. Gao Q., Kumar A., Singh L., Huibregtse J.M., Beaudenon S., Srinivasan S., Wazer D.E., Band H., and Band V. Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res. 62 11 (2002) 3315-3321
36. Garnett T.O., Filippova M., and Duerksen-Hughes P.J. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ. 13 11 (2006) 1915-1926
37. Gewies A. ApoReview: Introduction to Apoptosis (2003)
38. Gewin L., and Galloway D.A. E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J. Virol. 75 15 (2001) 7198-7201
39. Gewin L., Myers H., Kiyono T., and Galloway D.A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 18 18 (2004) 2269-2282
40. Giampieri S., Garcia-Escudero R., Green J., and Storey A. Human papillomavirus type 77 E6 protein selectively inhibits p53-dependent transcription of proapoptotic genes following UV-B irradiation. Oncogene 23 34 (2004) 5864-5870
41. Glaunsinger B.A., Lee S.S., Thomas M., Banks L., and Javier R. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene. 19 46 (2000) 5270-5280
42. Griffith J.D., Comeau L., Rosenfield S., Stansel R.M., Bianchi A., Moss H., and de Lange T. Mammalian telomeres end in a large duplex loop. Cell 97 4 (1999) 503-514
43. Grm H.S., and Banks L. Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent. J. Gen. Virol. 85 Pt 10 (2004) 2815-2819
44. Gross-Mesilaty S., Reinstein E., Bercovich B., Tobias K.E., Schwartz A.L., Kahana C., and Ciechanover A. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc. Natl. Acad. Sci. U. S. A. 95 14 (1998) 8058-8063
45. Grossman S.R., and Laimins L.A. E6 protein of human papillomavirus type 18 binds zinc. Oncogene J1- O 4 (1989) 1089-1093
46. Gu W., and Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90 4 (1997) 595-606
47. Harley C.B., Futcher A.B., and Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 345 6274 (1990) 458-460
48. Hasan U.A., Bates E., Takeshita F., Biliato A., Accardi R., Bouvard V., Mansour M., Vincent I., Gissmann L., Iftner T., Sideri M., Stubenrauch F., and Tommasino M. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 178 5 (2007) 3186-3197
49. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., and Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. Embo J. 8 12 (1989) 3905-3910
50. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37 (1965) 614-636
51. Hayflick L., and Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25 (1961) 585-621
52. Hershko A., and Ciechanover A. The ubiquitin system for protein degradation. Annu. Rev. Biochem. 61 (1992) 761-807
53. Hiscott J. Triggering the innate antiviral response through IRF-3 activation. J. Biol. Chem. 282 21 (2007) 15325-15329
54. Honda R., Tanaka H., and Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420 1 (1997) 25-27
55. Huang J., and Manning B.D. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412 2 (2008) 179-190
56. Huibregtse J.M., Scheffner M., and Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus type 16 or 18. EMBO J. 10 (1991) 4129-4135
57. Huibregtse J.M., Scheffner M., and Howley P.M. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell. Biol. 13 2 (1993) 775-784
58. Huibregtse J.M., Scheffner M., and Howley P.M. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell. Biol. 13 8 (1993) 4918-4927
59. Iftner T., Elbel M., Schopp B., Hiller T., Loizou J.I., Caldecott K.W., and Stubenrauch F. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. Embo J. 21 17 (2002) 4741-4748
60. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., and Yao T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. Embo J. 20 6 (2001) 1331-1340
61. Jackson S., Harwood C., Thomas M., Banks L., and Storey A. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev. 14 23 (2000) 3065-3073
62. James M.A., Lee J.H., and Klingelhutz A.J. HPV16-E6 associated hTERT promoter acetylation is E6AP dependent, increased in later passage cells and enhanced by loss of p300. Int. J. Cancer 119 8 (2006) 1878-1885
63. James M.A., Lee J.H., and Klingelhutz A.J. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J. Virol. 80 11 (2006) 5301-5307
64. Jin D.Y., Teramoto H., Giam C.Z., Chun R.F., Gutkind J.S., and Jeang K.T. A human suppressor of c-Jun N-terminal kinase 1 activation by tumor necrosis factor alpha. J. Biol. Chem. 272 41 (1997) 25816-25823
65. Jing M., Bohl J., Brimer N., Kinter M., and Vande Pol S.B. Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins. J. Virol. 81 5 (2007) 2231-2239
66. Karlseder J., Broccoli D., Dai Y., Hardy S., and de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283 5406 (1999) 1321-1325
67. Katzenellenbogen R.A., Egelkrout E.M., Vliet-Gregg P., Gewin L.C., Gafken P.R., and Galloway D.A. NFX1-123 and poly(A) binding proteins synergistically augment activation of telomerase in human papillomavirus type 16 E6-expressing cells. J. Virol. 81 8 (2007) 3786-3796
68. Kaufmann S.H., and Earnshaw W.C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256 1 (2000) 42-49
69. Kilian A., Bowtell D.D., Abud H.E., Hime G.R., Venter D.J., Keese P.K., Duncan E.L., Reddel R.R., and Jefferson R.A. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6 12 (1997) 2011-2019
70. Kiyono T., Hiraiwa A., Fujita M., Hayashi Y., Akiyama T., and Ishibashi M. Binding of high risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor supressor protein. PNAS 94 21 (1997) 11612-11616
71. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., and Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396 6706 (1998) 84-88
72. Klingelhutz A.J., Foster S.A., and McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380 6569 (1996) 79-82
73. Kuballa P., Matentzoglu K., and Scheffner M. The role of the ubiquitin ligase E6-AP in human papillomavirus E6-mediated degradation of PDZ domain-containing proteins. J. Biol. Chem. 282 1 (2007) 65-71
74. Kuhn U., and Wahle E. Structure and function of poly(A) binding proteins. Biochim. Biophys. Acta 1678 2-3 (2004) 67-84
75. Kuhne C., and Banks L. E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J. Biol. Chem. 273 51 (1998) 34302-34309
76. Kukimoto I., Aihara S., Yoshiike K., and Kanda T. Human papillomavirus oncoprotein E6 binds to the C-terminal region of human minichromosome maintenance 7 protein. Biochem. Biophys. Res. Commun. 249 1 (1998) 258-262
77. Kumar A., Zhao Y., Meng G., Zeng M., Srinivasan S., Delmolino L.M., Gao Q., Dimri G., Weber G.F., Wazer D.E., Band H., and Band V. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol. Cell. Biol. 22 16 (2002) 5801-5812
78. Lebel R., McDuff F.O., Lavigne P., and Grandbois M. Direct visualization of the binding of c-Myc/Max heterodimeric b-HLH-LZ to E-box sequences on the hTERT promoter. Biochemistry 46 36 (2007) 10279-10286
79. Lechner M.S., and Laimins L.A. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 68 7 (1994) 4262-4273
80. Lechner M.S., Mack D.H., Finicle A.B., Crook T., Vousden K.H., and Laimins L.A. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. Embo J. 11 8 (1992) 3045-3052
81. Lee C., and Laimins L.A. Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. J. Virol. 78 22 (2004) 12366-12377
82. Lee S.S., Weiss R.S., and Javier R.T. Binding of human virus oncoproteins to hDLG/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 6670-6675
83. Lee S.S., Glaunsinger B., Mantovani F., Banks L., and Javier R.T. Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J. Virol. 74 20 (2000) 9680-9693
84. Lee C., Wooldridge T.R., and Laimins L.A. Analysis of the roles of E6 binding to E6TP1 and nuclear localization in the human papillomavirus type 31 life cycle. Virology 358 1 (2007) 201-210
85. Leverrier S., Bergamaschi D., Ghali L., Ola A., Warnes G., Akgul B., Blight K., Garcia-Escudero R., Penna A., Eddaoudi A., and Storey A. Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria. Apoptosis 12 3 (2007) 549-560
86. Levy M.Z., Allsopp R.C., Futcher A.B., Greider C.W., and Harley C.B. Telomere end-replication problem and cell aging. J. Mol. Biol. 225 4 (1992) 951-960
87. Li X., and Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 70 7 (1996) 4509-4516
88. Lie A.K., Skarsvag S., Skomedal H., Haugen O.A., and Holm R. Expression of p53, MDM2, and p21 proteins in high-grade cervical intraepithelial neoplasia and relationship to human papillomavirus infection. Int. J. Gynecol. Pathol. 18 1 (1999) 5-11
89. Lipari F., McGibbon G.A., Wardrop E., and Cordingley M.G. Purification and biophysical characterization of a minimal functional domain and of an N-terminal Zn2+-binding fragment from the human papillomavirus type 16 E6 protein. Biochemistry 40 5 (2001) 1196-1204
90. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., and Berger S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 19 2 (1999) 1202-1209
91. Liu Y., Chen J.J., Gao Q., Dalal S., Hong Y., Mansur C.P., Band V., and Androphy E.J. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J. Virol. 73 9 (1999) 7297-7307
92. Liu X., Yuan H., Fu B., Disbrow G.L., Apolinario T., Tomaic V., Kelley M.L., Baker C.C., Huibregtse J., and Schlegel R. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J. Biol. Chem. 280 11 (2005) 10807-10816
93. Lowy D.R., and Howley P.M. Papillomaviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. Fourth ed. (2001), Lippincott Williams and Wilkins 2231-2264
94. Lu Z., Hu X., Li Y., Zheng L., Zhou Y., Jiang H., Ning T., Basang Z., Zhang C., and Ke Y. Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J. Biol. Chem. 279 34 (2004) 35664-35670
95. Mantovani F., and Banks L. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene 18 22 (1999) 3309-3315
96. Mantovani F., and Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20 54 (2001) 7874-7887
97. Matheu A., Maraver A., and Serrano M. The Arf/p53 pathway in cancer and aging. Cancer Res. 68 15 (2008) 6031-6034
98. McMurray H.R., and McCance D.J. Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression. J. Virol. 77 18 (2003) 9852-9861
99. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q., Bacchetti S., Haber D.A., and Weinberg R.A. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90 4 (1997) 785-795
100. Mietz J.A., Unger T., Huibregtse J.M., and Howley P.M. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. Embo J. 11 13 (1992) 5013-5020
101. Muller T., Hamm S., and Bauer S. TLR9-mediated recognition of DNA. Handb. Exp. Pharmacol. 183 (2008) 51-70
102. Munger K., Phelps W.C., Bubb V., Howley P.M., and Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63 10 (1989) 4417-4421
103. Murray-Zmijewski F., Slee E.A., and Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat. Rev., Mol. Cell Biol. 9 9 (2008) 702-712
104. Nakagawa S., and Huibregtse J.M. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell. Biol. 20 21 (2000) 8244-8253
105. Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H., Lingner J., Harley C.B., and Cech T.R. Telomerase catalytic subunit homologs from fission yeast and human. Science 277 5328 (1997) 955-959
106. Neumann A.A., and Reddel R.R. Telomere maintenance and cancer-look, no telomerase. Nat. Rev., Cancer 2 11 (2002) 879-884
107. Nomine Y., Masson M., Charbonnier S., Zanier K., Ristriani T., Deryckere F., Sibler A.P., Desplancq D., Atkinson R.A., Weiss E., Orfanoudakis G., Kieffer B., and Trave G. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol. Cell 21 5 (2006) 665-678
108. Oh S., Song Y.H., Kim U.J., Yim J., and Kim T.K. In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells. Biochem. Biophys. Res. Commun. 263 2 (1999) 361-365
109. Oh S.T., Kyo S., and Laimins L.A. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J. Virol. 75 12 (2001) 5559-5566
110. Pan H., and Griep A.E. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev. 9 17 (1995) 2157-2169
111. Passalaris T.M., Benanti J.A., Gewin L., Kiyono T., and Galloway D.A. The G(2) checkpoint is maintained by redundant pathways. Mol. Cell. Biol. 19 9 (1999) 5872-5881
112. Patel D., Huang S.M., Baglia L.A., and McCance D.J. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 18 18 (1999) 5061-5072
113. Peng Y.C., Breiding D.E., Sverdrup F., Richard J., and Androphy E.J. AMF-1/Gps2 binds p300 and enhances its interaction with papillomavirus E2 proteins. J. Virol. 74 13 (2000) 5872-5879
114. Pim D., and Banks L. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene 18 52 (1999) 7403-7408
115. Pina B., Berger S., Marcus G.A., Silverman N., Agapite J., and Guarente L. ADA3: a gene, identified by resistance to GAL4-VP16, with properties similar to and different from those of ADA2. Mol. Cell. Biol. 13 10 (1993) 5981-5989
116. Ristriani T., Nomine Y., Masson M., Weiss E., and Trave G. Specific recognition of four-way DNA junctions by the C-terminal zinc-binding domain of HPV oncoprotein E6. J. Mol. Biol. 305 4 (2001) 729-739
117. Ronco L.V., Karpova A.Y., Vidal M., and Howley P.M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12 (1998) 2061-2072
118. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 6 (1990) 1129-1136
119. Scheffner M., Munger K., Byrne J.C., and Howley P.M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. U. S. A. 88 13 (1991) 5523-5527
120. Scheffner M., Huibregtse J.M., Vierstra R.D., and Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75 (1993) 495-505
121. Schwarz S.E., Rosa J.L., and Scheffner M. Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7. J. Biol. Chem. 273 20 (1998) 12148-12154
122. Sekaric P., Cherry J.J., and Androphy E.J. Binding of human papillomavirus type 16 E6 to E6AP is not required for activation of hTERT. J. Virol. 82 1 (2008) 71-76
123. Shamanin V.A., and Androphy E.J. Immortalization of human mammary epithelial cells is associated with inactivation of the p14ARF-p53 pathway. Mol. Cell. Biol. 24 5 (2004) 2144-2152
124. Shamanin V.A., Sekaric P., and Androphy E.J. hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells. J. Virol. 82 8 (2008) 3912-3920
125. Shay J.W., and Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33 5 (1997) 787-791
126. Simmonds M., and Storey A. Identification of the regions of the HPV 5 E6 protein involved in Bak degradation and inhibition of apoptosis. Int. J. Cancer 123 10 (2008) 2260-2266
127. Singh L., Gao Q., Kumar A., Gotoh T., Wazer D.E., Band H., Feig L.A., and Band V. The high-risk human papillomavirus type 16 E6 counters the GAP function of E6TP1 toward small Rap G proteins. J. Virol. 77 2 (2003) 1614-1620
128. Song Z., Krishna S., Thanos D., Strominger J.L., and Ono S.J. A novel cysteine-rich sequence-specific DNA-binding protein interacts with the conserved X-box motif of the human major histocompatibility complex class II genes via a repeated Cys-His domain and functions as a transcriptional repressor. J. Exp. Med. 180 5 (1994) 1763-1774
129. Spain B.H., Bowdish K.S., Pacal A.R., Staub S.F., Koo D., Chang C.Y., Xie W., and Colicelli J. Two human cDNAs, including a homolog of Arabidopsis FUS6 (COP11), suppress G-protein- and mitogen-activated protein kinase-mediated signal transduction in yeast and mammalian cells. Mol. Cell. Biol. 16 12 (1996) 6698-6706
130. Spanos W.C., Geiger J., Anderson M.E., Harris G.F., Bossler A.D., Smith R.B., Klingelhutz A.J., and Lee J.H. Deletion of the PDZ motif of HPV16 E6 preventing immortalization and anchorage-independent growth in human tonsil epithelial cells. Head Neck 30 2 (2008) 139-147
131. Spanos W.C., Hoover A., Harris G.F., Wu S., Strand G.L., Anderson M.E., Klingelhutz A.J., Hendriks W., Bossler A.D., and Lee J.H. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J. Virol. 82 5 (2008) 2493-2500
132. Srivenugopal K.S., and Ali-Osman F. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Oncogene 21 38 (2002) 5940-5945
133. Steller M.A., Zou Z., Schiller J.T., and Baserga R. Transformation by human papillomavirus 16 E6 and E7: role of the insulin-like growth factor 1 receptor. Cancer Res. 56 21 (1996) 5087-5091
134. Sterlinko G.H., Weber M., Elston R., McIntosh P., Griffin H., Banks L., and Doorbar J. Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides. J. Mol. Biol. 335 4 (2004) 971-985
135. Struijk L., van der Meijden E., Kazem S., ter Schegget J., de Gruijl F.R., Steenbergen R.D., and Feltkamp M.C. Specific betapapillomaviruses associated with squamous cell carcinoma of the skin inhibit UVB-induced apoptosis of primary human keratinocytes. J. Gen. Virol. 89 Pt 9 (2008) 2303-2314
136. Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M., and Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59 3 (1999) 551-557
137. Thomas M., and Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 17 23 (1998) 2943-2954
138. Thomas M., and Banks L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J. Gen. Virol. 80 Pt 6 (1999) 1513-1517
139. Thomas M.C., and Chiang C.M. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol. Cell 17 2 (2005) 251-264
140. Thomas M., Massimi P., Jenkins J., and Banks L. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene 10 2 (1995) 261-268
141. Thomas M., Glaunsinger B., Pim D., Javier R., and Banks L. HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene 20 39 (2001) 5431-5439
142. Thomas M., Laura R., Hepner K., Guccione E., Sawyers C., Lasky L., and Banks L. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 21 33 (2002) 5088-5096
143. Tong X., and Howley P.M. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. PNAS 94 9 (1997) 4412-4417
144. Tungteakkhun S.S., Filippova M., Neidigh J.W., Fodor N., and Duerksen-Hughes P.J. The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain. J. Virol. 82 19 (2008) 9600-9614
145. Underbrink M.P., Howie H.L., Bedard K.M., Koop J.I., and Galloway D.A. The E6 proteins from multiple beta HPV types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J. Virol. 82 21 (2008) 10408-10417
146. Veldman T., Horikawa I., Barrett J.C., and Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J. Virol. 75 9 (2001) 4467-4472
147. Veldman T., Liu X., Yuan H., and Schlegel R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. U. S. A. 100 14 (2003) 8211-8216
148. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 15 22 (2001) 2922-2933
149. Wang J., Xie L.Y., Allan S., Beach D., and Hannon G.J. Myc activates telomerase. Genes Dev. 12 12 (1998) 1769-1774
150. Wu K.J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., and Dalla-Favera R. Direct activation of TERT transcription by c-MYC. Nat. Genet. 21 2 (1999) 220-224
151. Xu M., Luo W., Elzi D.J., Grandori C., and Galloway D.A. NFX1 interacts with mSin3A/histone deacetylase to repress hTERT transcription in keratinocytes. Mol. Cell. Biol. 28 15 (2008) 4819-4828
152. Yuan Z.M., Huang Y., Ishiko T., Nakada S., Utsugisawa T., Shioya H., Utsugisawa Y., Yokoyama K., Weichselbaum R., Shi Y., and Kufe D. Role for p300 in stabilization of p53 in the response to DNA damage. J. Biol. Chem. 274 4 (1999) 1883-1886
153. Yuan H., Fu F., Zhuo J., Wang W., Nishitani J., An D.S., Chen I.S., and Liu X. Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis. Oncogene 24 32 (2005) 5069-5078
154. Zeng M., Kumar A., Meng G., Gao Q., Dimri G., Wazer D., Band H., and Band V. Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J. Biol. Chem. 277 47 (2002) 45611-45618
155. Zheng L., Ding H., Lu Z., Li Y., Pan Y., Ning T., and Ke Y. E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6. Genes Cells 13 3 (2008) 285-294
156. Zimmermann H., Koh C.H., Degenkolbe R., O'Connor M.J., Muller A., Steger G., Chen J.J., Lui Y., Androphy E., and Bernard H.U. Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to downregulate CBP/p300-mediated transactivation by p53. J. Gen. Virol. 81 Pt. 11 (2000) 11-23